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Abstract
Background: We present a systematic search for regulatory elements in a 3.5 Mb region on human chromosome 20q13.12,
a region associated with a number of medical conditions such as type II diabetes and obesity.
Methodology/Principal Findings: We profiled six histone modifications alongside RNA polymerase II (PolII) and CTCF in two
cell lines, HeLa S3 and NTERA-2 clone D1 (NT2/D1), by chromatin immunoprecipitation using an in-house spotted DNA
array, constructed with 1.8 kb overlapping plasmid clones. In both cells, more than 90% of transcription start sites (TSSs) of
expressed genes showed enrichments with PolII, di-methylated lysine 4 of histone H3 (H3K4me2), tri-methylated lysine 4 of
histone H3 (H3K4me3) or acetylated H3 (H3Ac), whereas mono-methylated lysine 4 of histone H3 (H3K4me1) signals did not
correlate with expression. No TSSs were enriched with tri-methylated lysine 27 of histone H3 (H3K27me3) in HeLa S3, while
eight TSSs (4 expressed) showed enrichments in NT2/D1. We have also located several CTCF binding sites that are potential
insulator elements.
Conclusions/Significance: In summary, we annotated a number of putative regulatory elements in 20q13.12 and went on
to verify experimentally a subset of them using dual luciferase reporter assays. Correlating this data to sequence variation
can aid identification of disease causing variants.
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Introduction
Gene regulation is a complex process, requiring a large number
of proteins acting cooperatively on regulatory DNA sequences
which in turn are wrapped by histones. While instructions for the
recruitment of specific factors onto regulatory sites are partially
stored in the sequence, DNA should also be decorated with the
correct epigenetic markers to permit functional interactions
between trans-acting factors and DNA. Chromatin immunopre-
cipitation (ChIP) is a powerful technique which takes a snapshot of
the genome together with its associated proteins. This method is
currently the common method of choice (i) to map proteins onto
their genomic targets [1–5] and (ii) to understand the chromatin
context of functional genomic sites [6–12]. Histone tails can be
covalently modified by acetylation, phosphorylation, sumoylation,
ubiquitination and methylation. It is proposed that certain
combinations of histone modifications, so called the histone code,
partially sets the appropriate environment for cellular machineries
to act upon their target DNA sequences [13]. It was shown that in
humans 59 ends of transcriptionally active genes are enriched with
H3K4me3 and acetylated H3 [7,12,14–17], while transcription-
ally repressed regions carry modifications such as tri-methylated
lysine 9 (H3K9me3) and 27 of histone H3 [10,12,18–21].
H3K4me2 has been found on promoter of genes that are poised
for expression in undifferentiated and pluripotent cells, serving as a
preparatory signal for the start of transcription for lineage
commitment [22,23].
In embryonic stem cells, key developmental genes are occupied
by nucleosomes trimethylated at H3K27 and this modification is
required for silencing of such genes by polycomb repressor
complexes (PRCs) [18,19]. PRCs bind to developmentally
regulated genes and ensure their correct expression patterns to
preserve the pluripotency of cells. Although this silencing
mechanism is not yet clear, it seems that H3K27me3 facilitates
binding of such complexes in Drosophila [24]. Another study
showed that decreasing levels of H3K27me3 on promoter regions
of certain silenced genes is associated with their activation which
may contribute to oncogenesis depending on the functional nature
of erroneously activated silenced genes [25]. X-chromosome
inactivation in Drosophila females has also been linked to tri-
methylation of H3 at lysine 27 [11].
Promoters of key developmental genes often carry both
activatory (H3K4me3) and repressive (H3K27me3) histone marks
in embryonal stem cells [26]. Such regions are now called bivalent
domains, and they appear to be important to preserve the
differentiation potential of stem cells by keeping key developmen-
tal genes silent but poised for activation upon initiation of specific
differentiation routes. Indeed this bivalent marking of such regions
is lost in differentiated cells where they either have repressive or
active marking [27].
Mono-methylation at lysine 4 (H3K4me1) is often associated
with active chromatin in eukaryotes and target regions for binding
of chromodomains involved in chromatin structure [28,29]. This
modification is also found on distal regulatory elements [12,30].
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repressor on promoters or silencer sequences, or a chromatin
insulator protein [31]. It is also located as part of multi-protein
complexes regulating histone acetylation and deacetylation [32].
Human chromosome 20q13.12, (chr20:41,600,001–45,800,000,
NCBI build 36) is a gene rich region that has been associated with
a number of medical conditions such as diabetes [33]; obesity [34–
36]. It harbours a commonly deleted region (CDR) found in
patients with myeloproliferative disorders and myelodisplastic
syndromes [37], and ovarian cancer [38].
In this study, a 3.5 Mb region on 20q13.12 was investigated
using ChIP experiments performed with eight different antibodies
(Table 1) in two cell lines: HeLa S3, a cervical carcinoma, and
NT2/D1, a pluripotent embryonal carcinoma cell line. We
profiled three methylation status of H3K4 to map novel and
known promoters as well as distal regulatory elements. RNA
polymerase II antibody was used to investigate actively transcribed
regions. Antibody against H3K27me3 was used to map transcrip-
tionally silenced and/or developmentally regulated genes. Acety-
lated histone H3 and H4 antibodies were also included in the
study to further understand their correlation with histone
methylation. Lastly, we have used CTCF antibody to map
potential insulator elements. The enrichment profile of each
antibody was mapped using a custom-made tiling microarray with
a resolution of 1.8 kb (20676483 bp) (ArrayExpress Accession
Number A-MEXP-1441) and correlated to a detailed transcript
map already available for this region.
Materials and Methods
Cell Lines
HeLa S3, human cervical carcinoma cell line, was kindly
provided by Cancer Genome Project at the Sanger Institute.
NTERA-2 clone D1 (NT2/D1), human Caucasian pluripotent
embryonal carcinoma cell line purchased from European
Collection of Cell Cultures (ECAC). Both cell lines were grown
in high glucose (5 g/l) DMEM (Gibco, #41966029) supplemented
by 10% FBS and 16 antibiotic/antimycotic solution (Gibco,
#10378016) in a humidified incubator at 37uC and 5% CO2.
Chromatin Immunoprecipitation
ChIP experiments for all cells were carried out as described in
Koch (2007) [39]. Briefly, ,5610
7 cells were fixed with 0.37% or
1% formaldehyde. For histone modified antibodies, chromatin is
crosslinked for 15 minutes with 0.37% formaldehyde (FA). For
PolII antibody, chromatin is crosslinked for 1 hour with 1% FA
and for CTCF the chromatin is crosslinked for 15 minutes with
1% FA. Cells were lysed, collected nuclei was lysed with nuclear
lysis buffer. Chromatin was fragmented with a Sanyo Soniprep
sonicator to a size range of 300–700 bases with 30 seconds bursts
(Figure S1). After removal of a control aliquot (input chromatin),
diluted chromatin was incubated at 4uC overnight with relevant
antibodies (CTCF (sc15914, Santa Cruz Biotechnology),
H3K4me1 (ab8895, Abcam), H3K4me2 (ab7766, Abcam),
H3K4me3 (ab8580, Abcam), H3K27me3 (ab7312, Abcam),
H3Ac (at K9 and 14) (06-599, Upstate Biotech), H4Ac (at
K5,8,12 and 16) (06866, Upstate Biotech), PolII (ab513, Abcam),
Rabbit IgG (12-370, Upstate Biotech), Goat IgG (Santa Cruz
Biotechnology, #sc-3850)). Immune complexes were then precip-
itated with Agarose Protein A/G beads, washed and eluted.
Crosslinking of antibody/chromatin and input chromatin samples
were reversed by incubation at 65uC for 6 hours. Samples were
treated with Proteinase K overnight at 45uC. DNA was recovered
with water saturated phenol and chloroform, then ethanol-
precipitated.
Construction of Tilepath Arrays
1800 overlapping plasmid clones (2 kb inserts) were selected
from a sequenced chromosome 20 library in pUC18 [40]. Inserts
were amplified with AmpliTaq Gold Polymerase and pUC18
primers (95uC for 5 min then 30 cycles of 1 min at 95uC, 1 min at
60uC, and 4 min 72uC); forward primer contained an amino
group linked to sixth carbon atom at the 59 terminal for
attachment onto microarrays. Each fragment was printed in
triplicate on the array. The array and experiment design can be
accessed on ArrayExpress (http://www.ebi.ac.uk/microarray-as/
aer/login) using the accession number A-MEXP-1441.
Quantitative PCR
We have validated the enrichment signals of 37 regions using
quantitative PCR for all antibodies. Quantitative PCR was
performed according to manufacturer’s instructions (Eurogentec,
RT-SN2X-03+WOUN) on an ABI PRISMH 7700 – PCR: 2 mins
at 50uC followed by 10 min at 95uC, then 40 cycles of 15 sec at
95uC and 1 min at 60uC. Amplification levels of diluted input
chromatin were used as the baseline to determine amplification
levels of the ChIP samples. Ct values and amplification curves
were generated by ABI PRISMH 7700 analysis software. Primer
sequences are available upon request.
Labelling, Hybridisations and Array Scanning
ChIP DNA (ChDNA) and input chromatin (IP) were labelled
with cyanine-3 (Cy3) and cyanine-5 (Cy5) respectively by random
priming (BioPrime Labelling Kit, Invitrogen, #18094-011).
Table 1. The list of antibodies used in ChIP experiments.
Antibody Abbreviation Expected Genomic Regions
CTD of RNA polymerase II (phosphorylated at Serine 5) PolII Actively transcribed regions
mono-methylated Histone H3 at lysine 4 H3K4me1 Distal regulatory regions
di-methylated Histone H3 at lysine 4 H3K4me2 active promoters
tri-methylated Histone H3 at lysine 4 H3K4me3 active promoters
tri-methylated Histone H3 at lysine 27 H3K27me3 Silenced genes and heterochromatin?
acetylated Histone H3 at lysine 9 and 14 H3Ac active promoters
acetylated Histone H4 at lysine 5,8,12 and 16 H4Ac Chromatin remodeling
CTCF CTCF mainly insulator elements
doi:10.1371/journal.pone.0004479.t001
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columns (Pharmacia Amersham #275330-01). Equal amounts of
Cy3-IP and Cy5-ChDNA were mixed with human Cot1 DNA to
suppress repeat regions and precipitated with ethanol. Array
hybridisation was for 45 h at 37uC in the dark on a Tecan
HS4800 ProH station. Slides were washed with 16PBS/0.05%
Tween20 and 0.16SSC and HPLC purified water, dried on the
station and scanned using ScanArrayExpress HT (Perkin Elmer).
Light intensities on each spot on the array were digitalised with
ProScanArrayH Express software (Perkin Elmer) and ratio of Cy5
(experiment) to Cy3 signal (IP) is assigned as the signal of the
corresponding spot.
Data Analysis
Three biological and three technical replicates were performed
for each antibody. Average signal values were calculated for each
antibody (experiment) and its isotype antibody (control). The data
was floored and centred by dividing each data point by the median
of the dataset and log2-transformed. When the normalised signal
of a spot is 2.5 times higher than the standard deviation of the
data, it is considered enriched. Quantitative PCR of 37 regions
confirmed enrichment over input chromatin for 100% of the peaks
assigned using the above enrichment cut-offs for all antibodies.
Affymetrix Expression Arrays
GeneChip
TM Human Genome U133A 2.0 Expression Analysis
Arrays (Affymetrix, #900466) were used to determine the gene
expression profile of HeLa S3 and NT2/D1 cell lines; expression
values were calculated by GeneSpring GX Software (Agilent).
Dual Luciferase Assays
Candidate promoters were cloned into pGL3-basic (#E1751)
and pGL3-enhancer (#E1771) vectors. pGL3-promoter (#E1761)
and pGL3-control vector (#E1741) were used as positive controls.
pRL-SV40 vector (#E2231) was used as the internal control. We
also tested activity of inter-genic DNA fragments (of similar size)
with no known function to determine the background (negative
controls). Promoter constructs were transfected to HeLa S3 and
NT2/D1 cells using QIAGEN Effectene Transfection Reagent
(QIAGEN, #301425) according to manufacturer’s instructions. A
dual luciferase assay (Promega, #E1910) was used to measure the
luciferase and renilla activity within the transfected cells. Two days
after transfection, growth media was removed and cells were
washed with 100 mlo f1 6PBS. Then, cells were incubated in 16
Passive Cell Lysis Buffer for 20 min at room temperature for cell
lysis. Luciferase assays were performed with MicroLumat Plus LB
96V luminometer (Berthold Technologies). First, 50 mlo f
Luciferase Reagent II was injected to the lysate and luciferase
activity was measured for 10 sec. Then, 50 mlo fStop and GloH
reagent was injected to the lysate to stop the luciferase activity and
catalyse the renilla reaction, incubated for 1.6 sec and then renilla
activity was measured for 10 sec. All experiments were performed
in triplicates and repeated twice.
Results
In order to identify regulatory elements across a 3.5 Mb region
of human chromosome 20q13.12, we profiled two cell lines by
ChIP experiments against RNA polymerase II, CTCF and six
histone modifications (Table 1). Enrichment was measured with a
2 kb tilepath array spanning the region (see Methods). The
enrichment pattern of the region in both cell lines is shown in
Figure 1. The histograms of the enrichment signals of all
antibodies in both cell lines are shown in Figure S2. We also
surveyed gene expression levels of the 72 protein-coding genes in
the region using Affymetrix expression arrays and found 28 and 35
genes to be expressed in the HeLa S3 and NT2/D1 cell line
respectively.
Enrichment Profile of the TSS regions
In HeLa S3 cells, the regions containing the transcription start
sites (TSS)s of 11 genes showed enrichment with PolII antibody. In
addition, regions containing the TSSs of 10 genes showed
enrichment only with H3K4me3 (Table S1). PolII and/or
H3K4me3-enriched genes were highly or moderately expressed
although there were four lowly expressed genes that also showed
enrichments with either with PolII or H3K4me3.
In NT2/D1 cells, 28 genes showed enrichment with either PolII
or H3K4me3 with 13 having both (Table S2). All enriched genes
except two (SLC35C2 and C20ORF165) were highly or
moderately expressed.
Of the regions which contained a TSS and were enriched with
PolII and/or H3K4me3, nearly all showed enrichment with H3Ac
in both cell lines (Table S1 and S2). H4Ac enrichment was
observed in regions containing active TSSs only half the time (both
cell lines) which is expected since it is mainly associated with
chromatin structure changes and protein interactions [41].
Figure 2 shows the mono-, di- and tri-methylation profiles of
histone H3K4 within 10 kb distance of the start site of all the
genes. H3K4me1 does not appear to have a location preference;
the enrichment levels do not change greatly around the TSS
especially in NT2/D1 cells. Exceptions include PRKCBP1, which
is enriched with H3K4me1 up to 6 kb either direction of its start
site as well as NCOA3, ZNF335 and SDC4, which are enriched
across downstream sequences. Our results suggest that active
promoter regions are clearly marked with either H3K4me3 or
H3K4me2 whereas H3K4me1 does not have the same discrim-
inatory power for active TSSs. We have also investigated the
pairwise correlation of raw enrichment signals of each antibody in
each cell line and between the cell lines. Figure 3 displays pairwise
linear correlation coefficients for each pair of antibody signals on
the spots containing TSSs. Note that only those coefficients that
are significant at the 95% level based on a standard p-test are
shown as non-zero. The H3Ac, H3K4me2 and H3K4me3
enrichment levels were correlated well with each other in both
cells but not with H3K4me1. Notably, H3K4me1 signals were
positively correlated with H3K4me3 signals in HeLa S3 cells, but
there was no significant correlation found between H3K4me1 and
H3K4me3 in NT2/D1 cells. The H3K27me3 signals were
negatively correlated with those of H3K4me2, H3K4me3 and
H3Ac only in HeLa S3 cells, whereas there was no or little positive
correlation in NT2/D1 cells. This observation suggests a
differential usage of H3K27me3 modification between the two
cell lines. We have also included the correlation matrix of all
signals in both cell lines in Figure S4.
The above analysis identified novel promoters. A region 10 kb
upstream of PRKCBP1 (chr20:45,430,683–45,431,820 bp) showed
both strong PolII and H3K4me3 enrichment in NT2/D1 cells
(Figure 4). In VEGA Genome Browser (http://vega.sanger.ac.uk),
this region harbours the TSS of a GENSCAN prediction
supported by the 59 end of a human spliced EST (CN335160)
from embryonic stem cells. To test whether this region is a tissue-
specific alternative PRKCBP1 promoter, we cloned 1137 bp in a
luciferase reporter vector and transfected NT2/D1 cells. Figure S5
shows that this fragment has indeed promoter activity.
In the same cell line we also found a strong H3K4me3
enrichment in the second intron of SULF2 (chr20:45,818,232–
45,819,183 bp). Here, ENSEMBL annotation revealed the
A Histone Map of 20q13.12
PLoS ONE | www.plosone.org 3 February 2009 | Volume 4 | Issue 2 | e4479Figure 1. Normalised signals of all antibodies in both cell lines displayed in UCSC Genome Browser as custom tracks across human
20q12–13.2.
doi:10.1371/journal.pone.0004479.g001
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PLoS ONE | www.plosone.org 4 February 2009 | Volume 4 | Issue 2 | e4479Figure 2. Heat maps of H3K4me3 (A, D), H3K4me2 (B, E) and H3K4me1 (C, F) signals of 70 transcripts (sorted according to their
gene expression levels, the names of the genes can be found in the supplementary table 1 in the same order as here) in HeLa S3
cells and NT2/D1 cells respectively.
doi:10.1371/journal.pone.0004479.g002
Figure 3. Pairwise correlation coefficient matrix of enrichment signals for all antibodies on the spots containing TSSs in HeLa S3
cells (green rectangle), NT2/D1 cells (red rectangle), and between the two cell lines (remaining areas). Note that only coefficients which
are statistically significant at the 95% level, according to a standard p-test are shown as non-zero. The full correlation matrix without this significance
cut is provided in Figure S3.
doi:10.1371/journal.pone.0004479.g003
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PLoS ONE | www.plosone.org 5 February 2009 | Volume 4 | Issue 2 | e4479Figure 4. Enrichment pattern of PRKCBP1 (ZMNYD8) gene and its upstream region (chr20:45,270,000–45,510,000) with all
antibodies in both cell lines.
doi:10.1371/journal.pone.0004479.g004
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[42]. Constructs of this fragment were assessed for promoter activity
in both cell lines (Figure S6) and the results further supported its
function as an NT2/D1-specific alternative SULF2 TSS.
Partial histone code of distal regulatory elements
We assessed five histone modifications, namely H3K4me1,
H3K4me2, H3K4me3, H3Ac and H4Ac and found them to display
strikingly different profiles between the two cell lines. Figure 5 shows
the empirical cumulative distribution functions (i.e. the integrated
enrichment signaldistributions)forall antibodies inthetwo celllines.
Based on these, we have used a two-tailed Kolmogorov-Smirnov test
to find whether the distributions for a particular antibody are equal
inthetwocelllines.This test isverygeneraland doesnot assumeany
particular distribution of data, e.g. normal distribution. The null
hypothesis that the distributions are equal is tested against the
hypothesis that they are not equal. The resulting asymptotic
probabilities that the distributions are equal are shown in Figure 5.
In all cases, except CTCF, the probability that the distributions are
different is greater than 99.9%.
Across the region, no site showed enrichment with H3K4me1+
H3K4me3 or H3K4me1+H3K4me3+H3Ac, most likely due to the
fact that H3K4me2 is the intermediate step between H3K4me1 and
H3K4me3 [43]. HeLa S3 had three fold more H3K4me1-enriched
sites than NT2/D1 cells (Figure 6). Among the sites that were only
enriched with H3K4me1, 80% (in HeLa S3) and 85% (in NT2/D1)
werelocatedwithin inter- orintra-genicregions.Ten out of11 HeLa
S3 sites (90%) and 40 out of 54 NT2/D1 (73%) H3K4me2-enriched
sites were located within inter- or intra-genic regions indicating that
they do not possess the potential for further methylation. This
observation suggests that H3K4me2 may also play a functional role
for the regulation of distal regulatory or structural elements other
than TSSs.
Sites that were enriched with H3K4me1+H3K4me2 were not
close to annotated TSSs, while 90% of the sites that were enriched
with H3K4me1+H3K4me2+H3Ac were close or overlapping
TSSs in both cells. This observation can lead to two conclusions; (i)
H3 acetylation may indeed have a stimulatory effect for a site to be
enriched in H3K4me3 [44], or (ii) H3Ac may not be a common
histone modification in regulatory elements other than promoters.
One region lying within the first intron of the ADA (42,704,657
to 42,706,871 bp) showed enrichment with H3K4me1 and
H3K4me2 in HeLa S3 cells (Figure 7). The same region and its
2 kb upstream and downstream flanks (42,702,249 to 42,708,995)
also showed H3K4me1 and H3Kme2 enrichment in NT2/D1
cells. A known intronic enhancer of the ADA promoter (42,706,026
and 42,709,030 bp) is located in this region containing three
DNase hypersensitive sites [45]. This observation supports the
hypothesis that mono-methylated histone H3 could be a marker
for distal enhancer elements [12,30].
A high number of sites containing or overlapping conserved
non-genic sequences (CNGs) were found to be enriched with
H3K4me1, H3K4me2, H3Ac or H4Ac in both cell lines. The
region, chr20:42,749,148–42,766,245 bp, which is annotated to
only harbour a non-coding novel transcript (RP11-445H22.4),
displayed a complex enrichment profile only in HeLa S3 cells
(Figure 7). The first two kilobases of this region is enriched with
PolII but there is no H3K4me3 enrichment suggestive of a tissue
specific distal regulatory element whose function is regulated by
histone modifications. The PolII enrichment may reflect an
Figure 5. Empirical cumulative distribution functions for all antibodies, for the two different cell lines (HeLa S3 and NT2/D1), using
the full data set. The probability of the two cell-line distributions being equal, according to a two-tailed Kolmogorov-Smirnov test, is shown in each
panel (the null hypothesis being that the distributions are equal, and the alternative hypothesis that they are not equal).
doi:10.1371/journal.pone.0004479.g005
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promoter of its target gene located elsewhere in the genome which
could lead to cross-linking and co-immunoprecipitation with the
initiation complex (i.e. PolII acts as a bridge between the two
sequences). Note that this region was only enriched with
H3K4me1 and H3K4me2 in NT2/D1 suggesting that this
hypothetical element could be inactive in this cell line. To
investigate its putative enhancer activity, the region was cloned to
an enhancer-testing vector and transfected to both cell lines. We
found moderate enhancer activity in both transfected cell lines
which supports our hypothesis of an element with distal regulatory
activity (Figure S7). However, the fact that it shows moderate
enhancer activity in both cell lines suggests that tissue specificity is
most likely regulated by chromatin modifications and further
experiments are required to test this hypothesis.
H3K27me3 enrichment profile varies greatly between the
cell lines
ChIP-chip experiments carried out in HeLa S3 cells revealed 17
regions enriched with H3K27me3 of which none was close to an
annotated TSS (Table S4). In NT2/D1 cells, we found enrichment
in 75 inter- and intra-genic regions as well as in the TSSs of eight
genes (4 expressed); three also have H3K4me3 enrichment (Table
S5). Except one intra-genic region, none of the H3K27me3-
enriched regions showed enrichment with PolII or H3Ac or H4Ac
(both cell lines). Spatially, H3K27me3-enriched regions in HeLa
S3 confined within circa 1 Mb (right end) whereas they were
scattered across the entire region in NT2/D1 (Figure 1).
SLC12A5, which encodes for a membrane protein responsible
for co-transporting potassium and chloride ions across the cell
membrane and its expression is restricted to neurons in the central
nervous system and retina playing an important role in neuronal
development [46]. We note that the core promoter of SLC12A5
did not show any activity in dual luciferase promoter assays we
performed (both cell lines: data not shown). As expected SLC12A
was not expressed in either cell line, but it showed very different
enrichment patterns between the cell lines (Figure S8). In NT2/D1
cells, TSS-containing and downstream flanking spots were
enriched with H3K4me3, H3Ac and H3K27me3 and the gene
body is enriched with H3K27me3 across its sequence. In HeLa S3
cells, only the downstream TSS flanking region was enriched with
H3K4me3 and H3Ac. The SLC12A5 promoter can be classified as
‘‘bivalent’’ in NT2/D1 cells since it appears enriched in both
H3K27me3 and H3K4me3 [26]. We also found moderate
H3K4me3 and strong H3K4me2 enrichment on the spot carrying
the 39 UTR (NT2/D1 cells only). The 39 UTR of SLC12A5 lies
within a CpG island (length=1856 bp, GC%=64.3, Obs(CpG)/
Exp(CpG)=0.757) which overlaps a promoter (FirstExon) and
TSS prediction (Eponine). A possible explanation is that this
putative promoter drives an antisense RNA, a mechanism to
ensure that the gene is inactive [47].
Another membrane protein, CDH22 (cadherin-like 22) whose
expression is restricted to brain and plays a role in neuronal and
non-neuronal cell development [48], showed H3K27me3 enrich-
ment both at the TSS and around it together with H3K4me2 and
H3K4me3 (NT2/D1 cells only). Therefore, its promoter is also
classified as ‘‘bivalent’’. In HeLa S3 we found PolII enrichment
along with several other activation histone modifications in the
sixth intron of CDH22 (chr20:44,269,828–44,269,597), which
might be a potential silencer.
All the H3K27me3 enriched genes have tissue or developmental
specific expression profiles, and they have the same expression
profile in HeLa S3 cells except CDH22, which is expressed in
NT2/D1 but not in HeLa S3. The difference in H3K27me3
enrichment profile between the two cell lines might be due to their
different origin, as NT2/D1 is established from a malignant germ
line tumour and can differentiate to neurons whereas HeLa S3
cells do not have such ability.
Several inter- and intra-genic sites were enriched with
CTCF
CTCF is a versatile transcription factor functioning as an
activator or repressor on promoter or silencer sequences, or a
chromatin insulator protein (reviewed in [31]). It is also located as
part of multi-protein complexes regulating acetylation status of
histones on promoters [32].
Figure 6. Plots of number of occurrences of possible modified histone combinations with H3Ac in HeLa S3 and NT2/D1 cells
respectively.
doi:10.1371/journal.pone.0004479.g006
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PLoS ONE | www.plosone.org 8 February 2009 | Volume 4 | Issue 2 | e4479Figure 7. Enrichment profile of the 140 kb region (chr20:42,665,000–42,805,000) containing one known and one putative enhancer
and one putative insulator with all antibodies in both cell lines.
doi:10.1371/journal.pone.0004479.g007
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regions in both HeLa S3 and NT2/D1 cells. Interestingly, more
than 95% of the CTCF-enriched sites were common and the
overall enrichment signal distributions were similar between the
two cell lines (Figure 5). The statistical significance of the signal
distributions being equal is about 10%, and hence we cannot
conclude that they are equal – but equally neither that they are
different. In total, 40 inter-genic and 18 intra-genic regions
showed enrichment with CTCF in both cell lines.
None of the eight genes, whose start site was enriched with CTCF,
was expressed in HeLa S3 cells whereas in NT2/D1, start sites of
three expressed and two non-expressed genes were enriched with
CTCF (Table S6). Such enrichment pattern suggests a silencing role
for CTCF in HeLa S3 cells. The TSS of ZNF335 which is not
expressed in HeLa S3 was enriched with PolII, H3K4me3 and
H3Ac. This gene encodes for a zinc finger protein which indirectly
activates ligand-bound nuclear hormone receptors [49]. Its core
promoter showed activity in luciferase assays only when cloned with
the SV40 enhancer (HeLa S3 cells, data not shown). Since we
detected no expression of ZNF335 in this cell line despite the factthat
the promoter region seems to be actively transcribed, there should be
a mechanism which can either halt the initiation complex or decrease
the mRNA stability. Importantly, three intronic sites within ZNF335
were enriched with CTCF in HeLa S3 cells. It is known that CTCF
can act as a repressor by having a negative effect on the elongation
process of the transcription [50] and the enriched intra-genic sites
might be the mediator of such a mechanism regulating ZNF335
expression. In NT2/D1 where this gene is expressed, and its start site
was enriched with PolII, H3K4me3 and H3Ac, only one of the three
intronic sites showed CTCF-enrichment.
Recent studies have reported genome wide surveys of both
predicted [5] and experimentally verified [51] CTCF binding sites
with 70 of them (45 experimentally verified, 25 predictions) in our
region. Of the 45 experimentally identified CTCF binding sites, 32
were detected in our study in both cell lines (Figure S9). Lowering
our detection threshold, it was possible to detect another 8 without
including any false positives. No enrichment was seen on five of the
reported in our study. When we looked at the 25 predicted CTCF
binding sites, eight were detected in our study in both cells and a
further, three in only one cell line. We detected an additional seven
sites when we lowered the detection threshold (no extra false
positives). Nine predicted sites did not show any enrichment in our
study and one was not represented on our array.
A 2.2 kb long region (R7 in Table S5) was enriched with CTCF
in both cell lines and it is a potential insulator since it lies between
the intronic enhancer of the house-keeping gene ADA and tissue-
specific promoter of WISP2 (Figure 7). The intronic ADA enhancer
is a strong regulatory element that can increase ADA promoter
activity in a tissue-specific manner [45]. Enhancer elements exert
their effects over long distances in an orientation-independent
manner. So this enhancer can be a problem if it was to act on a
promoter such as that of the WISP2 which has a tissue-specific
expression and is probably functioning in bone turnover [52]. An
insulator element, as the one proposed here, can solve this
problem by blocking the communication between the enhancer
and the promoter located on the other side of the insulator.
There are five candidate insulator elements between 43.1 and
43.5 Mb (Figure S10). Each putative insulator lies between two
candidate enhancers thereby possibly blocking the communication
between these elements to ensure proper regulation of the
neighbouring genes. It is important to note that all the genes in
this window exhibit a tissues-specific expression pattern [53].
There are 18 CTCF-enriched regions located in introns (Table
S6). HNF4A, RIMS4, KCNS1 and EYA2 are not expressed in either
cell lines whereas PKIG, STK4 and DNTTIP are expressed in both.
Except STK4, none of the genes with an intronic CTCF-
enrichment showed PolII or H3K4me3 enrichment on their start
sites. These regions might be silencers as CTCF plays a major role
as a repressor in silencer complexes [32,50,54].
TSSs of the three non-expressed genes (KCNS1, WFDC10A and
C20ORF165) enriched with H3K4me3, but not with H3Ac,
showed enrichments with CTCF in NT2/D1 cells (Table S6). The
CTCF might play a role in these regions by inhibiting histone
acetylation complexes. In HeLa S3, KCNS1 and WFDC10A were
also enriched with CTCF but did not show enrichment with
H3K4me3 or H3Ac. This suggests that if CTCF functions as a
repressor on the promoter of these genes its recruitment is
probably independent of the region’s H3K4me3 status since we
detected binding in two different chromatin environments.
Discussion
In this study, we present a partial histone map of a 3.5 Mb
region of human chromosome 20q13.12 and identify novel
promoter and distal regulatory elements. Analysis of histone
modification profiles at TSSs verified that H3K4me1 does not
have a discriminatory power for actively transcribing TSS,
whereas tri-methylated H3K4 clearly marks active promoters.
We found two novel tissue-specific promoters for PKRCBP1 and
SULF2 by utilising the histone code of active promoters.
We went on to locate several putative tissue specific distal
regulatory elements (enhancers, silencers and insulators) and we
observed striking differences in the histone code profiles in the two
cell lines examined (Figure 1 and 5). The differences in
H3K27me3 profiles between the two cell lines suggested that
H3K27me3 behaves as an antagonist of activatory histone
modifications such as H3Ac, H3K4me2 and H3K4me3 in HeLa
S3 cells whereas in NT2/D2 no such relation is observed (Figure 3
and Figure S4).
The 20q13.12 region has been implicated in several disease
studies and the histone code, expression and reporter gene assays
provided here would provide a framework to integrate sequence
variation data and aid the design of functional studies to
characterise disease causing variants. This systematic approach
can be applied to all genomic intervals resulting from genome wide
association studies of common disease and other complex traits.
Supporting Information
Figure S1 Size distributions of ChIP samples prepared by
crosslinking with 0.37% formaldehyde for 15 minutes from HeLa
S3 (Lane 11) and NT2/D1 (Lane 12) cells run on Agilent
BioAnalyser.
Found at: doi:10.1371/journal.pone.0004479.s001 (0.04 MB TIF)
Figure S2 Histograms of enrichment signals of all antibodies in
HeLa S3 and NT2/D1 cells. The overlapping bars are shown in
dark green.
Found at: doi:10.1371/journal.pone.0004479.s002 (1.41 MB TIF)
Figure S3 Pairwise correlation coefficient matrix of enrichment
signals for all antibodies on the spots containing TSSs in HeLa S3
cells (green rectangle), NT2/D1 cells (red rectangle), and between
the two cell lines (remaining areas).
Found at: doi:10.1371/journal.pone.0004479.s003 (0.89 MB TIF)
Figure S4 Pairwise correlation coefficient matrix of enrichment
signals for all antibodies on all the spots in HeLa S3 cells (green
rectangle), NT2/D1 cells (red rectangle), and between the two cell
lines (remaining areas). Note that only coefficients which are
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test are shown as non-zero.
Found at: doi:10.1371/journal.pone.0004479.s004 (0.90 MB TIF)
Figure S5 Upstream region of PRKCBP1 (chr20:45,431,095–
45,431,820 bp) was cloned to pGL3-basic vectors in both
directions (S;sense, AS:antisense) and transfected to both cells
together with internal control plasmid. The promoter construct in
the antisense direction (in the same direction with PRKCBP1)
showed ,18 fold promoter activity compared to null and negative
control constructs in NT2/D1 cells but no significant activity was
observed in HeLa S3 cells.
Found at: doi:10.1371/journal.pone.0004479.s005 (0.16 MB TIF)
Figure S6 Promoter assays of a region within the first intron of
SULF2 (chr20:45,818,232–45,819,183 bp) in both cell lines. The
region was cloned to pGL3-basic vectors in both directions
(S;sense, AS:antisense) and transfected to both cells together with
internal control plasmid. The construct in the antisense direction
(in the same direction with SULF2) showed ,2-fold promoter
activity compared to null construct in NT2/D1 cells.
Found at: doi:10.1371/journal.pone.0004479.s006 (0.12 MB TIF)
Figure S7 Dual Luciferase Assays of a segment of the region
spanning chr20:42,749,148–42,766,245 bp (denoted as put_en-
hancer). It showed around 5 fold activity than randomly chosen
inter-genomic fragments (of same length) in both cell lines.
Found at: doi:10.1371/journal.pone.0004479.s007 (0.10 MB TIF)
Figure S8 Enrichment profile of SLC12A5 with H3Ac,
H3K4me2, H3K4me3 and H3K27me3 antibodies in both cell
lines.
Found at: doi:10.1371/journal.pone.0004479.s008 (1.00 MB TIF)
Figure S9 CTCF binding sites reported in our study and
CTCFBSDB.
Found at: doi:10.1371/journal.pone.0004479.s009 (2.58 MB TIF)
Figure S10 The region spanning from 43,100,000 to
43,425,000 bp where there are five candidate insulators shown
as blue boxes on the insulator track. There are two more tracks,
displaying H3K4me1 and H3K4me2 enriched regions in HeLa S3
(Enhancers_H track) and NT2/D1 (Enhancers_N track) as
possible cis-acting regulatory elements.
Found at: doi:10.1371/journal.pone.0004479.s010 (0.43 MB TIF)
Table S1 Enrichment profile of 70 transcripts in HeLa S3 cells.
‘‘*’’ denotes enrichment above threshold.
Found at: doi:10.1371/journal.pone.0004479.s011 (0.02 MB
XLS)
Table S2 Enrichment profile of 70 transcripts in NT2/D1 cells.
‘‘*’’ denotes enrichment above threshold.
Found at: doi:10.1371/journal.pone.0004479.s012 (0.04 MB
XLS)
Table S3 Genes sorted according to their expression levels in
both cells (X-axis of Figure 1)
Found at: doi:10.1371/journal.pone.0004479.s013 (0.04 MB
XLS)
Table S4 Enrichment profile of H3K27me3-enriched regions in
HeLa S3 cells. ‘‘*’’ denotes enrichment above threshold.
Found at: doi:10.1371/journal.pone.0004479.s014 (0.02 MB
XLS)
Table S5 Enrichment profile of H3K27me3-enriched regions in
NT2/D1 cells. ‘‘*’’ denotes enrichment above threshold.
Found at: doi:10.1371/journal.pone.0004479.s015 (0.04 MB
XLS)
Table S6 List of regions and their enrichment profiles enriched
with CTCF in HeLa S3 and NT2/D1 cells. ‘‘*’’ denotes
enrichment above threshold.
Found at: doi:10.1371/journal.pone.0004479.s016 (0.05 MB
XLS)
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